ライフサイエンスコーパス: lisdexamfetamine

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 nerally consistent with the known profile of lisdexamfetamine.

2 Lisdexamfetamine administration.

3 ng relapse criteria were 3.7% (5 of 136) for lisdexamfetamine and 32.1% (42 of 131) for placebo.

4 inge eating and related psychopathology, and lisdexamfetamine and topiramate reduced weight in adults

5 Lisdexamfetamine demonstrated superiority over placebo o

6 Evaluate lisdexamfetamine dimesylate (LDX) augmentation of antide

7 The efficacy and safety of lisdexamfetamine dimesylate (LDX) vs placebo in binge ea

8 This multicenter study examined lisdexamfetamine dimesylate (LDX), a d-amphetamine prodr

9 Lisdexamfetamine dimesylate at dosages of 30, 50, or 70

10 To assess lisdexamfetamine dimesylate maintenance of efficacy in a

11 pen-label phase (dose optimization, 4 weeks [lisdexamfetamine dimesylate, 50 or 70 mg]; dose maintena

12 12) were randomized to placebo or continued lisdexamfetamine during a 26-week, double-blind, randomi

13 Further investigation of lisdexamfetamine in BED is ongoing.

14 Lisdexamfetamine (LDX) has been suggested to be a safe a

15 Lisdexamfetamine (mean difference [MD], -6.50 [CI, -8.82

16 sdexamfetamine responders (placebo, n = 138; lisdexamfetamine, n = 137), the observed proportions of

17 ased sympathetic nervous system arousal, and lisdexamfetamine reduced weight and appetite.

18 e, 50 or 70 mg]; dose maintenance, 8 weeks), lisdexamfetamine responders (</=1 binge eating day per w

19 Of 275 randomized lisdexamfetamine responders (placebo, n = 138; lisdexamf

20 Cognitive behavioral therapy, lisdexamfetamine, SGAs, and topiramate reduced binge eat

21 months was lower in participants continuing lisdexamfetamine than in those randomized to placebo.

22 system arousal occurred more frequently with lisdexamfetamine than placebo (relative risk range, 1.63

23 The hazard for relapse was lower with lisdexamfetamine than placebo.

24 ased on a Cox proportional hazards model for lisdexamfetamine vs placebo, was 0.09 (95% CI, 0.04-0.23

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。